Drug Profile
Research programme: leuprorelin-based cancer therapy - Curaxis
Alternative Names: leuprolide acetate - CuraxisLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Curaxis Pharmaceutical Corporation
- Class Gonadotropins; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma(Late-stage disease) in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)